Sompharmaceutical
Developing novel somatostatin analogue therapies and diagnostics for rare diseases
- Stage Prototype Ready
- Industry Biotechnology
- Location Chemin des Croisettes, Epalinges, VD, Switzerland
- Currency USD
- Founded August 2012
- Employees 4
- Website sompharmaceuticals.com
Company Summary
Sompharmaceuticals S.A. a Swiss based biopharmaceutical company based at the Biopôle in Epalinges-Lausanne, Switzerland is focused on developing novel anti-tumour somatostatin analogue (SSA) peptide medicines and diagnostics for patients with rare diseases, which have unmet medical needs and major market opportunities. Contact: john.watson@sompharmaceuticals.com
Team
-
Alan HarrisProfessor
Founder , Chairman
25 years experience in Pharma/Biotech industry
VP Med Affairs Schering Plough-Merck; Head Endocrinology Pfizer; CMO NPS Pharma
Led clinical development of Sandostatin™ (octreotide), the leading analogue which has 90% of the worldwide market and is worth $1.5B per year. -
Viktor BoerlinDr
Head Clinical Development
30 years drug development experience in pharma industry
Former Head Dept. Neuroendocrinology Sandoz/Novartis -
Hervè PorchetDr
Head Clinical Operations
20 years drug development experience
Therapeutic areas; reproductive medicine, endocrinology, osteoporosis, CNS, pain, hepatology, infectious diseases, pulmonary diseases, oncology and cardiovascular diseases.
Advisors
-
N/ALawyerUnconfirmedN/AAccountantUnconfirmed
Previous Investors
-
NoneUnconfirmed
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.